Efficacy and Safety Study of E2007 in Migraine Prophylaxis
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
This was a 22-week, prospective, randomized, double-blind, placebo-controlled, multicenter,
parallel-group study that included a 4-week Baseline Phase at the beginning and a 4-week
single-blind placebo Safety Phase at the end of the study.